Kito Fronhas

#Oncology lover / Son / Dad / husband / 🐕 / #healthylifestyle / #Vegan / Tweets are mine - RTs may be endorsements 😜

[Dana-Farber News @DanaFarberNews]

Dana-Farber research supports FDA approval of pembrolizumab-belzutifan combination for higher-risk clear cell kidney cancer after surgery. Research led by @DrChoueiri of @DanaFarber_GU

Read more here: https://t.co/DvEWSBikoe

[Katy Beckermann @katy_beckermann]

I wrote about where belzutifan fits across the RCC continuum in @OncJournal. Today's adjuvant approval (LITESPARK-022) sits right next to LITESPARK-011 in the post-PD-(L)1 setting, where belzutifan + lenvatinib beat cabozantinib on PFS (14.8 vs 10.7 mo, HR 0.70) and ORR (53% vs 40%) and most impactful nearly doubled duration of response.

The throughline: earlier HIF-2α targeting may buy durability, but patient selection and careful monitoring of toxicity, and OS immature in both datasets

👉 https://t.co/UdmAtLjpoy

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

General-purpose LLMs outperform specialized clinical AI tools on medical benchmarks
@NatureMedicine

Frontier models beat OpenEvidence and UpToDate Expert AI across every evaluation, including real physician queries rated by blinded clinicians.

Not unexpected, but surprising nonetheless!

https://t.co/ptNGex1L12

[The ASCO Post @ASCOPost]

🚨 #FDAApproval: The @US_FDA approved capivasertib (Truqap) with abiraterone and prednisone for PTEN-deficient metastatic #ProstateCancer.

Approval based on the phase III CAPItello-281 trial, which showed improved radiographic PFS.

🔗 https://t.co/N4UdKUMSgm

[NEJM @NEJM]

Original Article: Intravascular Ultrasound–Guided or Angiography-Guided Complex High-Risk PCI (IVUS-CHIP trial) https://t.co/W0pXLVOkLS

Editorial: IVUS — A Zigzag Path to Success https://t.co/rmA2iesDHw

#Cardiology

[Cristiane D Bergerot, PhD, FASCO @crisbergerot]

Patients selected for NAC had less favorable baseline characteristics, but progression-free and overall survival were comparable to primary surgery after adjustment for prognostic factors @JCOOA_ASCO

https://t.co/2GYjv9XIPv

[The ASCO Post @ASCOPost]

💉 Could #GLP1 RAs help reduce #cancer risk?
🆕 observational data found a significantly lower incidence of obesity-related cancers among GLP-1 RA users, with the greatest reduction seen with tirzepatide.
🔹 Aparna A. Kamat, MD | @Annals_Oncology
🔗 https://t.co/wwx96oTsQt

[CA: A Cancer Journal for Clinicians @CACancerJournal]

HR+/HER2- metastatic breast cancer is driven by diverse biology & evolving resistance. @DrDebuTripathy et al discuss precision treatment advances through targeted therapies, genomic profiling, & patient-centered decision making.

🔗 https://t.co/DU86kXa5qB

@OncoAlert

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Breaking new👉 today @US_FDA approved capivasertib (oral AKT inhibitor) for the metastatic HSPC/APMS #prostatecancer with PTEN deficiency👉personalized medicine continues to leap forward👉Capitello-281 ph3 trial summary👇 @OncoAlert @urotoday @AUC3_Official

[Katy Beckermann @katy_beckermann]

AI is already here in how we prognosticate mHSPC.

One biopsy-based score, validated in two RPh3 trials:
📉 5-yr prostate cancer death, low-volume (STAMPEDE): 27% with a low score → 43% with a high score
📈 5-yr overall survival (CHAARTED): 83% with a low score → 39% with a high score

🎯 Prognostic, and not predictive yet

#ProstateCancer #mHSPC #AIinMedicine #GUonc #AIinOncology

[NEJM @NEJM]

Presented at #EAACICongress2026:

In a phase 3, randomized trial of lonvo-z, an in vivo gene editing therapy, patients with hereditary angioedema who received the drug had a significantly lower attack rate than those who received placebo. Full HAELO trial results: https://t.co/qBliFvKFKl

@EAACI_HQ

[The ASCO Post @ASCOPost]

🧬 A new era in #pancreaticcancer?
In this commentary, Drs. Ajay Prakash & Emil Lou (@cancerassassin1) examine how the phase III RASolute 302 trial positions daraxonrasib as a potential new standard in KRAS-mutant metastatic pancreatic cancer.
Read more ➡️ https://t.co/NxXCJAIhuY

[Cristiane D Bergerot, PhD, FASCO @crisbergerot]

🚨We want YOU🚨

Only a few days remain to submit your research to the @ASCO #ASCOQLTY26
@RyanNipp

Share your work on quality improvement, PROs, care delivery, survivorship, digital health, & person-centered cancer care

⏰ Deadline: June 16, 11:59 PM ET

https://t.co/aHUQ2L8xfe

[Toni Choueiri, MD @DrChoueiri]

Just in (again, Friday FDA notices): The @US_FDA
approved Capivasertib (oral AKT inhibitor) for metastatic Hormone-Sensitive prostate Cancer with PTEN deficiency (by IHC; 90%+).

4/30: ODAC voted 7-1 for a favorable benefit-risk profile based on the CAPItello-281 Phase III trial results (HR: 0.81)

https://t.co/07Zjtxod8b

Another example of personalized medicine in #oncology

With HIF2 inhibitor Belzutifan approval today (https://t.co/2jcC5AdYFc), it is a great day for #GU Cancer patients

@OncoAlert @AUC3_Official @DanaFarber_GU @PCFnews @OncBrothers @OncLive

[Katy Beckermann @katy_beckermann]

Clinical AI tool that reads a routine H&E slide from diagnosis to identify which mHSPC patients benefit from ARSI enzalutamide. APIC, presented at #ASCO26 from ENZAMET.

APIC was derived in CHAARTED and locked before ENZAMET analysis. Independent validation in 492 patients from the ENZAMET biomarker cohort.

Outcomes:
🎯 APIC-Negative (64%): +18.2% 5-yr OS from enzalutamide
🎯 APIC-Positive (36%): -3.2% 5-yr OS from enzalutamide

Significant treatment-biomarker interaction. Holds in multivariable analysis adjusting for volume, timing, PS, and Gleason. Not explained by docetaxel use.

No special assay or new test. Just a pathology slide you probably already have.

#mHSPC #ProstateCA #GUonc #ASCO26 #AIinMedicine #AIinOncology

[Jarushka Naidoo @DrJNaidoo]

#iTOX @GustaveRoussy
Thanks #AurelienMarabelle for the invitation to present on long-term ICI tox, key priorities:
- collect nuanced irAE data beyond clinical trial followup
- time tox, financial tox, HRQOL
- balancing tox+response: "impact"
@CancerCentreIre @OncoAlert #LCSM

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

🚨@OncoAlert ALERT ‼️ Take your #ASCO26 work further...

#ASCOQLTY26 abstracts are due in ONE WEEK. Don't miss the opportunity to present your patient-centered, QI, access, and/or equity work to active & engaged clinicians, researchers, & advocates.

👉 https://t.co/Rjc7JAvXpm

[JAMA @JAMA_current]

Presented this weekend at #ADASciSessions:

Implementation of the $35 out-of-pocket cap for #Insulin among Medicare Part D users reduced average insulin costs and stabilized expenses, with increased use and adherence seen for patients with previously high out-of-pocket costs.

https://t.co/l6D6Fbzyt7

[ACS Journal Cancer @JournalCancer]

Oncology clinical trials have long relied on RECIST criteria to define progression. In a recent commentary, @MSKCancerCenter researchers propose further study and reporting of how treatment failure is characterized.

https://t.co/uJDtN8nTTm

@EChrisDee @PatelOncology @OncoAlert

[Laura Bukavina @LauraBukavinaMD]

Glad our @EUplatinum RCC review is being utilized for AUA course review by an amazing teacher @drphil_urology 🙏 https://t.co/U4FdP8E6NH. Here is a nice overview of increasing incidence due to imaging 📈 with no change in mortality